April 3 (Reuters) - The U.S. Food and Drug Administration's website showed that two doses of Eli Lilly's weight-loss drug, Zepbound, would be available only in limited amounts through end of April 2024 due to increased demand. (Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
787 USD | +3.19% | +1.55% | +35.01% |
05-15 | Health Care Up on Momentum -- Health Care Roundup | DJ |
05-15 | UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.01% | 688B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Some doses of Lilly's Zepbound in limited availability, US FDA says